THE APEX TIMES
A report said Eli Lilly found no unauthorized access to its own systems following a vendor-related incident. Separately, an extortion group claims it has patient and prescriber information affecting 1.2 million people.
Eli Lilly is responding to a vendor-related cyber incident after an extortion group said it has stolen data that could include patient and prescriber information for 1.2 million people, according to a report published Monday by Yahoo Finance.
The report said Lilly determined that there was no unauthorized access to its own systems. A person familiar with the matter was cited in the article discussing the company’s internal assessment, including the conclusion that Lilly’s systems were not breached.
While Lilly’s findings were described as limited to its own environment, the report framed the extortion claims as involving patient and prescriber data. The article also identified the alleged actor as “n0n,” which said it could release or leak information as part of an extortion effort.
The report did not provide additional technical details about the scope of the vendor incident, what type of vendor was involved, or whether Lilly received any formal notification from the vendor or a law-enforcement or regulator channel. It also did not say whether Lilly has begun or completed any downstream steps such as notifying patients, prescribers, or healthcare partners.
At this point, the public information described in the report is primarily about Lilly’s internal determination and the extortion group’s public assertions. Extortion posts are common in cyber incidents, but they do not necessarily confirm that the data is accurate, current, or actually transferable or usable.
The incident lands in a broader healthcare context where pharmaceutical companies and their ecosystems, including vendors that support sales operations, data processing, and IT services, are frequently targeted. Patient and prescriber information is especially sensitive because it can be used for identity theft, fraud, and targeted social engineering.
For Eli Lilly, the business impact would depend less on the company’s own system security determination and more on whether any third parties or data flows were affected, what the vendor access enabled, and whether any data was actually exfiltrated or altered. The report, however, did not supply information on those points.
What to watch next is whether Lilly provides a more complete account through a formal statement, a regulatory disclosure, or a public security update, and whether authorities or the vendor involved provide additional clarity about the incident timeline and the nature of any claimed data.
A report says an extortion group claims it obtained patient and prescriber information, but Lilly said there was no unauthorized access to its systems.
Bertolini, who previously oversaw Aetna through CVS’s takeover, argued that the roughly $70 billion acquisition functioned more as a workaround than a cure. The comments land shortly after CVS said it plans to split into two businesses.
The deal, announced by Eli Lilly, centers on acquiring Calytrix Bio for $1.5 billion. Investors are watching how the purchase could reshape the company’s development pipeline and expectations for future growth.
At ObesityWeek 2026, Eli Lilly reported late-stage results for EloraTZP and continued to spotlight retatrutide and Foundayo, extending the company’s efforts to treat obesity and related complications.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...